Defendant
9 cases as defendant.
Company overview. Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is an Irish-domiciled, publicly traded biopharmaceutical company headquartered at Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. It was founded in 2003 by Bruce Cozadd (who remains chairman and CEO) and has been listed on Nasdaq since its 2007 IPO. Reported headcount is roughly 2,890 employees (year-end 2025), with trailing revenue around $4.1–4.3 billion. It is not a subsidiary; it is the publicly listed parent. Operational hubs include Palo Alto and Philadelphia, with manufacturing in Ireland, Italy, and the U.S.
Products / operations. Jazz develops and commercializes medicines in neuroscience and oncology. Neuroscience: Xywav and Xyrem (sodium oxybate) for narcolepsy and idiopathic hypersomnia, and Epidiolex (cannabidiol) for severe epilepsies. Oncology: Rylaze/Enrylaze, Zepzelca, Ziihera (zanidatamab), Defitelio, Vyxeos, and Modeyso, plus pipeline candidates such as dordaviprone and JZP815. Portfolio expansion has come largely through acquisition — notably GW Pharmaceuticals (2021, ~$7.2 billion) and Chimerix (2025, ~$935 million).
Patent-litigation posture. Jazz is an operating company, not an NPE. In the structured data it appears in 23 tracked matters and as plaintiff in zero. Its defendant-side record here reflects antitrust and reimbursement litigation over its oxybate franchise rather than patent-assertion suits against it. The venue cluster is N.D. Cal. and the Northern District of Illinois, alongside D. Minn. and D. Mass.; no Eastern District of Texas presence.
Notable cases and context. Most tracked matters are consolidated in In re Xyrem (Sodium Oxybate) Antitrust Litigation, MDL No. 20-md-02966-RS (N.D. Cal.), brought by payors including UnitedHealthcare, the Blue Cross and Blue Shield Association, the Government Employees Health Association, the City of Providence, and the Self-Insured Schools of California. Plaintiffs alleged pay-for-delay agreements with generic manufacturers and "product hopping" from Xyrem to Xywav. The court granted final approval in October 2025 to $195 million in settlements ($145 million from Jazz, $50 million from Hikma). A separate qui tam matter, United States ex rel. Leonardo Sorgi v. Jazz Pharmaceuticals (D. Mass., 2021), also names the company. Jazz has stated it entered settlements in the Xyrem antitrust litigation; the merits of individual claims are not assessed here.
Antitrust action by United HealthCare Services against Jazz in D. Minn. It cites the '106 patent among patents at issue and was terminated April 15, 2021.
Antitrust action in which drugpatentwatch lists the '219 patent.
Antitrust case citing the '275 patent as part of an alleged Orange Book/patent-thicket scheme; terminated Apr. 15, 2021 in D. Minn.
Antitrust action terminated April 15, 2021, likely transferred to the Xyrem MDL.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; settled and voluntarily dismissed with prejudice July 16, 2025.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; terminated at N.D. Ill. July 14, 2020.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; terminated at N.D. Ill. July 15, 2020.
Xyrem antitrust action; US 7,765,107 is listed among the patents at issue in the narrative.
MDL antitrust litigation in which the '650 patent is identified in complaints as one of the Xyrem patents central to the alleged evergreening/sham-litigation scheme. Final settlement approval order entered Oct. 27, 2025.